Presentation: Phase 2 study of SNT-5505 in myelofibrosis
Filed with ASX · · 20 pages · English
In the deck
Earlier from Syntara
- Trading Halt
- Response to ASX Price Query
- Pause in Trading
- Appendix 4E and Annual Report to shareholders
- Half Yearly Report and Accounts
Later from Syntara
- Interim data in Phase 2 study of SNT-5505 in myelofibrosis
- Equity Raising Presentation
- Placement
- Acceleration of skin scarring program
- Quarterly Activities Report
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara